MELBOURNE & SYDNEY, Australia--(BUSINESS WIRE)--Amneal Pharmaceuticals Pty Ltd and Actavis Australia Pty Ltd, a subsidiary of Actavis plc (NYSE: ACT), today announced they have signed a binding letter of intent which provides that Amneal intends to acquire substantially all of Actavis’ in-country generic pharmaceuticals business for an agreed price, subject to completion of confirmatory due diligence and definitive agreements.
Help employers find you! Check out all the jobs and post your resume.
